1.	VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113971, NCT01205230
2.	Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG107769, NCT00387764
3.	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 108844, NCT00720941
4.	Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Refractory or Relapsed Metastatic Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-62072, EORTC 62072, EU-20887, NCT00794521, PALETTE, GSK-VEG110727, EUDRACT-2008-001307-33
5.	Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110655, NCT00866697
6.	Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113046, NCT01064310
7.	GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG102616, UCLA-0508053-01, UCLA-0506058-01, GSK-VEG102616, NCT00244764
8.	Phase II Study of GW786034 in Patients With Relapsed or Refractory Advanced or Metastatic Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EORTC-62043, GSK-EORTC-62043, EUDRACT-2004-004378-10, NCT00297258
9.	Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG20006, NCT00256880
10.	A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 104450, NCT00281632
11.	Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105192, NCT00334282
12.	Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG20007, NCT00347919
13.	Pazopanib In Combination With Lapatinib In Adult Patients With Relapsed Malignant Glioma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG102857, NCT00350727
14.	Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105290, NCT00367679
15.	Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG105281, NCT00430781
16.	Pazopanib in Treating Patients With Advanced Neuroendocrine Cancer Phase: Phase II Type: Treatment Status: Closed Age: 21 and over Sponsor: NCI, Other Protocol IDs: 2006-0077, P30CA016672, MDA-2006-0077, CDR0000537034, MDACC 2006-0077, 7650, NCT00454363
17.	Phase II Study of Pazopanib Hydrochloride in Patients With Stage IV or Recurrent Nasopharyngeal Carcinoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: CTRG-NP05/25/06, 7623, SINGAPORE-NCC-06-01, NCC-06-01, NCT00454142
18.	Phase II Study of Pazopanib Hydrochloride in Patients With Recurrent Glioblastoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-0602, NABTC-06-02, 737754, NCT00459381, NCI-07-C-0138
19.	Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00202, N01CM62201, CDR0000538086, 14954A, UCCRC-14954A, 7659, NCT00454571
20.	Phase II Study of Pazopanib Hydrochloride in Patients With Malignant Pleural Mesothelioma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCCTG-N0623, N0623, NCT00459862
21.	Pazopanib in Treating Patients With Metastatic Urothelial Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00203, MC0553, CDR0000543460, N01CM62205, MAYO-MC0553, 7661, NCT00471536
22.	Phase II Randomized Study of Pazopanib Hydrochloride With Versus Without Bicalutamide in Patients With Hormone-Refractory Prostate Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-058, 7640, PMH-10036920, PHL-058, NCT00486642
23.	Phase II Study of Pazopanib in Patients With Recurrent or Metastatic Invasive Breast Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: PMH-PHL-057, 7638, PHL-057, NCT00509587
24.	Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG108838, NCT00558103
25.	Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VEG110190, NCT00561795